Patents by Inventor Todd Juan
Todd Juan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11155876Abstract: The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.Type: GrantFiled: June 21, 2018Date of Patent: October 26, 2021Assignee: AMGEN INC.Inventors: Daniel J Freeman, Todd Juan, Robert Radinsky
-
Publication number: 20190048423Abstract: The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.Type: ApplicationFiled: June 21, 2018Publication date: February 14, 2019Applicant: AMGEN INC.Inventors: Daniel J Freeman, Todd Juan, Robert Radinsky
-
Patent number: 10030270Abstract: The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.Type: GrantFiled: June 14, 2012Date of Patent: July 24, 2018Assignee: AMGEN, INCInventors: Daniel Freeman, Todd Juan, Robert Radinsky
-
Patent number: 8546107Abstract: Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3?-kinase (“PI3K”), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant PI3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described.Type: GrantFiled: July 15, 2011Date of Patent: October 1, 2013Assignee: Amgen Inc.Inventors: Daniel J Freeman, Todd Juan, Robert Radinsky
-
Patent number: 8420332Abstract: The present invention provides Tumor Endothelial Marker 5? (TEM5?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5? polypeptides.Type: GrantFiled: March 28, 2012Date of Patent: April 16, 2013Assignee: Amgen Inc.Inventor: Todd Juan
-
Publication number: 20120328620Abstract: Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3?-kinase (“PI3K”), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant PI3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described.Type: ApplicationFiled: July 15, 2011Publication date: December 27, 2012Applicant: AMGEN INCInventors: Daniel J. FREEMAN, Todd JUAN, Robert RADINSKY
-
Publication number: 20120264129Abstract: The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.Type: ApplicationFiled: June 14, 2012Publication date: October 18, 2012Inventors: Daniel Freeman, Todd Juan, Robert Radinsky
-
Publication number: 20120237959Abstract: The present invention provides Tumor Endothelial Marker 5? (TEM5?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5? polypeptides.Type: ApplicationFiled: March 28, 2012Publication date: September 20, 2012Applicant: AMGEN INC.Inventor: Todd Juan
-
Patent number: 8163878Abstract: The present invention provides Tumor Endothelial Marker 5? (TEM5?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5? polypeptides.Type: GrantFiled: March 22, 2010Date of Patent: April 24, 2012Assignee: Amgen Inc.Inventor: Todd Juan
-
Patent number: 8071372Abstract: The present invention provides Tumor Endothelial Marker 5? (TEM5?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5? polypeptides.Type: GrantFiled: August 9, 2010Date of Patent: December 6, 2011Assignee: Amgen Inc.Inventor: Todd Juan
-
Patent number: 7981605Abstract: Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3?-kinase (“Pl3K”), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant Pl3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant Pl3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant Pl3K, and/or mutant B-Raf are also described.Type: GrantFiled: February 23, 2006Date of Patent: July 19, 2011Assignee: Amgen Inc.Inventors: Daniel J. Freeman, Todd Juan, Robert Radinsky
-
Publication number: 20110033472Abstract: The present invention provides Tumor Endothelial Marker 5? (TEM5?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5? polypeptides.Type: ApplicationFiled: August 9, 2010Publication date: February 10, 2011Applicant: AMGEN INC.Inventor: Todd Juan
-
Publication number: 20110003755Abstract: The present invention provides Tumor Endothelial Marker 5? (TEM5?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5? polypeptides.Type: ApplicationFiled: March 22, 2010Publication date: January 6, 2011Applicant: AMGEN INC.Inventor: Todd Juan
-
Patent number: 7771965Abstract: The present invention provides Tumor Endothelial Marker 5? (TEM5?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5? polypeptides.Type: GrantFiled: October 15, 2002Date of Patent: August 10, 2010Assignee: Amgen Inc.Inventor: Todd Juan
-
Publication number: 20090053763Abstract: The present invention provides Tumor Endothelial Marker 7? (TEM7?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM7? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TEM7? polypeptides.Type: ApplicationFiled: March 10, 2008Publication date: February 26, 2009Applicant: Amgen, Inc.Inventors: Todd Juan, Michael Brian Bass, Jonathan Daniel Oliner
-
Publication number: 20080293055Abstract: The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.Type: ApplicationFiled: March 11, 2008Publication date: November 27, 2008Inventors: Daniel FREEMAN, Todd Juan, Robert Radinsky
-
Publication number: 20070048754Abstract: Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3?-kinase (“Pl3K”), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant Pl3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant Pl3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant Pl3K, and/or mutant B-Raf are also described.Type: ApplicationFiled: February 23, 2006Publication date: March 1, 2007Inventors: Daniel Freeman, Todd Juan, Robert Radinsky
-
Publication number: 20030105019Abstract: The present invention provides Tumor Endothelial Marker 5&agr; (TEM5&agr;) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5&agr; polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5&agr; polypeptides.Type: ApplicationFiled: October 15, 2002Publication date: June 5, 2003Applicant: Amgen Inc. A Corporation of the State of DelawareInventor: Todd Juan
-
Publication number: 20030092025Abstract: The present invention provides Tumor Endothelial Marker 7&agr; (TEM7&agr;) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM7&agr; polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TEM7&agr; polypeptides.Type: ApplicationFiled: May 28, 2002Publication date: May 15, 2003Applicant: Amgen, Inc., A Corporation of the State of DelawareInventors: Todd Juan, Michael Brian Bass, Jonathan Daniel Oliner